FIELD: chemistry.
SUBSTANCE: invention relates to biotechnology and immunology. Disclosed is interferon which is conjugated with polyethylene glycol, where polyethylene glycol is bonded to the interferon via an azo group.
EFFECT: invention increases circulation time of interferon in blood while preserving a considerable fraction of its biological activity.
4 cl, 2 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ERYTHROPOETIN CONJUGATED WITH POLYETHYLENE GLYCOL | 2010 |
|
RU2433134C1 |
| POLYETHYLENE GLYCOL DERIVATIVES CONTAINING AROMATIC DIAZO GROUP | 2010 |
|
RU2439091C1 |
| NOVEL FUNCTIONALLY ACTIVE, HIGHLY PURE, STABLE CONJUGATE OF INTERFERON α WITH POLYETHYLENE GLYCOL, REPRESENTED BY ONE PEG- NH-IFN POSITIONAL ISOMER, WITH IMPROVED IMMUNOGENICITY, WITH PROLONGED BIOLOGICAL ACTION, SUITABLE FOR MEDICAL APPLICATION, AND IMMUNOLOGICAL AGENT BASED THEREON | 2010 |
|
RU2447083C1 |
| MEDICINAL AGENT BASED ON MODIFIED ALPHA INTERFERON WITH PROLONGED THERAPEUTIC ACTION | 2008 |
|
RU2382048C1 |
| CONJUGATES OF PROTEIN AND POLYETHYLENE GLYCOL DERIVATIVE, PHARMACEUTICAL COMPOSITION, METHOD FOR CONTROL OF VIRAL INFECTION | 2004 |
|
RU2298560C2 |
| INTERFERON CONJUGATES AND METHOD FOR PRODUCTION THEREOF | 2011 |
|
RU2466138C1 |
| PAGYLATED INTERFERON AGAINST VIRAL INFECTION | 2004 |
|
RU2311930C2 |
| INTERFERON CONJUGATES | 1997 |
|
RU2180595C2 |
| PEG-MODIFIED HUMAN INTERFERON β-1a MOLECULE WITH ANTIVIRAL, IMMUNOMODULATORY AND ANTIPROLIFERATIVE ACTIVITY, WITH IMPROVED STABILITY, REDUCED IMMUNOGENICITY, IMPROVED PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS, SUITABLE FOR MEDICAL USE, AND IMMUNOBIOLOGICAL FORMULATION BASED THEREON | 2013 |
|
RU2576372C2 |
| HYBRID PROTEIN HAVING PROLONGED ACTION, BASED ON RECOMBINANT HUMAN INTERFERON ALPHA-2 (VARIANTS), METHOD OF ITS PRODUCTION AND STRAIN OF Saccharomyces cerevisiae FOR IMPLEMENTING THIS METHOD (VERSIONS) | 2013 |
|
RU2515913C1 |
